The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Liposomal-based Drug Market Research Report 2024

Global Liposomal-based Drug Market Research Report 2024

Publishing Date : Sep, 2023

License Type :
 

Report Code : 1791108

No of Pages : 108

Ask Your Query
Synopsis
Nanoparticle drug delivery systems are engineered technologies that use nanoparticles for the targeted delivery and controlled release of therapeutic agents. The modern form of a drug delivery system should minimize side-effects and reduce both dosage and dosage frequency. Recently, nanoparticles have aroused attention due to their potential application for effective drug delivery.
Global Liposomal-based Drug market is projected to reach US$ 9855.2 million in 2029, increasing from US$ 5019 million in 2022, with the CAGR of 10.0% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Liposomal-based Drug market research.
The liposomes nanoparticle drugs market is driven by the increasing demand for targeted drug delivery systems and the potential of liposomes to improve therapeutic efficacy. Liposomes are nanoscale vesicles composed of lipid bilayers that can encapsulate various drugs and deliver them to specific target sites in the body. This targeted drug delivery offers benefits such as reduced side effects, improved drug bioavailability, and enhanced therapeutic outcomes. As the prevalence of chronic diseases rises and the need for personalized medicine grows, liposomes nanoparticle drugs gain popularity in the pharmaceutical industry. Moreover, advancements in nanotechnology and biopharmaceutical research have led to the development of innovative liposomal formulations for a wide range of diseases. However, the market also faces challenges, including the high costs associated with liposomal drug development and production. Additionally, regulatory complexities related to nanomedicines and the need for comprehensive safety evaluations pose obstacles to market growth. To leverage the market's potential fully, manufacturers need to focus on cost-effectiveness, quality assurance, and robust clinical data to gain regulatory approvals and establish the efficacy and safety of liposomes nanoparticle drugs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Liposomal-based Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Johnson & Johnson
Sun Pharmaceutical
CSPC
Kinyond
Teva
Fudan-Zhangjiang
Zydus Cadila
TTY Biopharma
Pacira
Luye Pharma
Leadiant Biosciences
Ipsen
Sayre Therapeutics
Jazz
Alnylam
Bausch Health
Acrotech Biopharma
Takeda
Chiesi Farmaceutici
Gilead Sciences
Segment by Type
Liposomes Drugs
Lipid Nanoparticle Drugs
Segment by Application
Hospital
Retail Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Liposomal-based Drug report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Liposomal-based Drug Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Liposomes Drugs
1.2.3 Lipid Nanoparticle Drugs
1.3 Market by Application
1.3.1 Global Liposomal-based Drug Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Liposomal-based Drug Market Perspective (2018-2029)
2.2 Liposomal-based Drug Growth Trends by Region
2.2.1 Global Liposomal-based Drug Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Liposomal-based Drug Historic Market Size by Region (2018-2023)
2.2.3 Liposomal-based Drug Forecasted Market Size by Region (2024-2029)
2.3 Liposomal-based Drug Market Dynamics
2.3.1 Liposomal-based Drug Industry Trends
2.3.2 Liposomal-based Drug Market Drivers
2.3.3 Liposomal-based Drug Market Challenges
2.3.4 Liposomal-based Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Liposomal-based Drug Players by Revenue
3.1.1 Global Top Liposomal-based Drug Players by Revenue (2018-2023)
3.1.2 Global Liposomal-based Drug Revenue Market Share by Players (2018-2023)
3.2 Global Liposomal-based Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Liposomal-based Drug Revenue
3.4 Global Liposomal-based Drug Market Concentration Ratio
3.4.1 Global Liposomal-based Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Liposomal-based Drug Revenue in 2022
3.5 Liposomal-based Drug Key Players Head office and Area Served
3.6 Key Players Liposomal-based Drug Product Solution and Service
3.7 Date of Enter into Liposomal-based Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Liposomal-based Drug Breakdown Data by Type
4.1 Global Liposomal-based Drug Historic Market Size by Type (2018-2023)
4.2 Global Liposomal-based Drug Forecasted Market Size by Type (2024-2029)
5 Liposomal-based Drug Breakdown Data by Application
5.1 Global Liposomal-based Drug Historic Market Size by Application (2018-2023)
5.2 Global Liposomal-based Drug Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Liposomal-based Drug Market Size (2018-2029)
6.2 North America Liposomal-based Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Liposomal-based Drug Market Size by Country (2018-2023)
6.4 North America Liposomal-based Drug Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Liposomal-based Drug Market Size (2018-2029)
7.2 Europe Liposomal-based Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Liposomal-based Drug Market Size by Country (2018-2023)
7.4 Europe Liposomal-based Drug Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Liposomal-based Drug Market Size (2018-2029)
8.2 Asia-Pacific Liposomal-based Drug Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Liposomal-based Drug Market Size by Region (2018-2023)
8.4 Asia-Pacific Liposomal-based Drug Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Liposomal-based Drug Market Size (2018-2029)
9.2 Latin America Liposomal-based Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Liposomal-based Drug Market Size by Country (2018-2023)
9.4 Latin America Liposomal-based Drug Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Liposomal-based Drug Market Size (2018-2029)
10.2 Middle East & Africa Liposomal-based Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Liposomal-based Drug Market Size by Country (2018-2023)
10.4 Middle East & Africa Liposomal-based Drug Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Johnson & Johnson
11.1.1 Johnson & Johnson Company Detail
11.1.2 Johnson & Johnson Business Overview
11.1.3 Johnson & Johnson Liposomal-based Drug Introduction
11.1.4 Johnson & Johnson Revenue in Liposomal-based Drug Business (2018-2023)
11.1.5 Johnson & Johnson Recent Development
11.2 Sun Pharmaceutical
11.2.1 Sun Pharmaceutical Company Detail
11.2.2 Sun Pharmaceutical Business Overview
11.2.3 Sun Pharmaceutical Liposomal-based Drug Introduction
11.2.4 Sun Pharmaceutical Revenue in Liposomal-based Drug Business (2018-2023)
11.2.5 Sun Pharmaceutical Recent Development
11.3 CSPC
11.3.1 CSPC Company Detail
11.3.2 CSPC Business Overview
11.3.3 CSPC Liposomal-based Drug Introduction
11.3.4 CSPC Revenue in Liposomal-based Drug Business (2018-2023)
11.3.5 CSPC Recent Development
11.4 Kinyond
11.4.1 Kinyond Company Detail
11.4.2 Kinyond Business Overview
11.4.3 Kinyond Liposomal-based Drug Introduction
11.4.4 Kinyond Revenue in Liposomal-based Drug Business (2018-2023)
11.4.5 Kinyond Recent Development
11.5 Teva
11.5.1 Teva Company Detail
11.5.2 Teva Business Overview
11.5.3 Teva Liposomal-based Drug Introduction
11.5.4 Teva Revenue in Liposomal-based Drug Business (2018-2023)
11.5.5 Teva Recent Development
11.6 Fudan-Zhangjiang
11.6.1 Fudan-Zhangjiang Company Detail
11.6.2 Fudan-Zhangjiang Business Overview
11.6.3 Fudan-Zhangjiang Liposomal-based Drug Introduction
11.6.4 Fudan-Zhangjiang Revenue in Liposomal-based Drug Business (2018-2023)
11.6.5 Fudan-Zhangjiang Recent Development
11.7 Zydus Cadila
11.7.1 Zydus Cadila Company Detail
11.7.2 Zydus Cadila Business Overview
11.7.3 Zydus Cadila Liposomal-based Drug Introduction
11.7.4 Zydus Cadila Revenue in Liposomal-based Drug Business (2018-2023)
11.7.5 Zydus Cadila Recent Development
11.8 TTY Biopharma
11.8.1 TTY Biopharma Company Detail
11.8.2 TTY Biopharma Business Overview
11.8.3 TTY Biopharma Liposomal-based Drug Introduction
11.8.4 TTY Biopharma Revenue in Liposomal-based Drug Business (2018-2023)
11.8.5 TTY Biopharma Recent Development
11.9 Pacira
11.9.1 Pacira Company Detail
11.9.2 Pacira Business Overview
11.9.3 Pacira Liposomal-based Drug Introduction
11.9.4 Pacira Revenue in Liposomal-based Drug Business (2018-2023)
11.9.5 Pacira Recent Development
11.10 Luye Pharma
11.10.1 Luye Pharma Company Detail
11.10.2 Luye Pharma Business Overview
11.10.3 Luye Pharma Liposomal-based Drug Introduction
11.10.4 Luye Pharma Revenue in Liposomal-based Drug Business (2018-2023)
11.10.5 Luye Pharma Recent Development
11.11 Leadiant Biosciences
11.11.1 Leadiant Biosciences Company Detail
11.11.2 Leadiant Biosciences Business Overview
11.11.3 Leadiant Biosciences Liposomal-based Drug Introduction
11.11.4 Leadiant Biosciences Revenue in Liposomal-based Drug Business (2018-2023)
11.11.5 Leadiant Biosciences Recent Development
11.12 Ipsen
11.12.1 Ipsen Company Detail
11.12.2 Ipsen Business Overview
11.12.3 Ipsen Liposomal-based Drug Introduction
11.12.4 Ipsen Revenue in Liposomal-based Drug Business (2018-2023)
11.12.5 Ipsen Recent Development
11.13 Sayre Therapeutics
11.13.1 Sayre Therapeutics Company Detail
11.13.2 Sayre Therapeutics Business Overview
11.13.3 Sayre Therapeutics Liposomal-based Drug Introduction
11.13.4 Sayre Therapeutics Revenue in Liposomal-based Drug Business (2018-2023)
11.13.5 Sayre Therapeutics Recent Development
11.14 Jazz
11.14.1 Jazz Company Detail
11.14.2 Jazz Business Overview
11.14.3 Jazz Liposomal-based Drug Introduction
11.14.4 Jazz Revenue in Liposomal-based Drug Business (2018-2023)
11.14.5 Jazz Recent Development
11.15 Alnylam
11.15.1 Alnylam Company Detail
11.15.2 Alnylam Business Overview
11.15.3 Alnylam Liposomal-based Drug Introduction
11.15.4 Alnylam Revenue in Liposomal-based Drug Business (2018-2023)
11.15.5 Alnylam Recent Development
11.16 Bausch Health
11.16.1 Bausch Health Company Detail
11.16.2 Bausch Health Business Overview
11.16.3 Bausch Health Liposomal-based Drug Introduction
11.16.4 Bausch Health Revenue in Liposomal-based Drug Business (2018-2023)
11.16.5 Bausch Health Recent Development
11.17 Acrotech Biopharma
11.17.1 Acrotech Biopharma Company Detail
11.17.2 Acrotech Biopharma Business Overview
11.17.3 Acrotech Biopharma Liposomal-based Drug Introduction
11.17.4 Acrotech Biopharma Revenue in Liposomal-based Drug Business (2018-2023)
11.17.5 Acrotech Biopharma Recent Development
11.18 Takeda
11.18.1 Takeda Company Detail
11.18.2 Takeda Business Overview
11.18.3 Takeda Liposomal-based Drug Introduction
11.18.4 Takeda Revenue in Liposomal-based Drug Business (2018-2023)
11.18.5 Takeda Recent Development
11.19 Chiesi Farmaceutici
11.19.1 Chiesi Farmaceutici Company Detail
11.19.2 Chiesi Farmaceutici Business Overview
11.19.3 Chiesi Farmaceutici Liposomal-based Drug Introduction
11.19.4 Chiesi Farmaceutici Revenue in Liposomal-based Drug Business (2018-2023)
11.19.5 Chiesi Farmaceutici Recent Development
11.20 Gilead Sciences
11.20.1 Gilead Sciences Company Detail
11.20.2 Gilead Sciences Business Overview
11.20.3 Gilead Sciences Liposomal-based Drug Introduction
11.20.4 Gilead Sciences Revenue in Liposomal-based Drug Business (2018-2023)
11.20.5 Gilead Sciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock